F rancis Collins recently pointed out that " [d]espite dramatic advances in the molecular pathogenesis of disease, translation of basic biomedical research into safe and effective clinical applications remains a slow, expensive, and failure-prone endeavor." 1 The field of heart failure is a perfect example. Drug development for the treatment of heart failure is littered with good ideas that have not moved from the research bench to the clinical arena as well as compounds that showed great promise in the laboratory and in early phase II trials (vesnarinone and etanercept) 2,3 but were complete disappointments in large phase III clinical trials. 4, 5 In this issue of Circulation Research, Michael Bristow describes the pathways that led to the successful development of and wide-spread utilization of ␤-adrenergic receptor (AR) antagonists (␤-blockers) for the treatment of heart failure. 6 This story provides a quintessential example of how the clinical and translational sciences can inform and facilitate drug discovery through a close linkage between basic science and clinical investigation, a collaborative and multidisciplinary approach to drug development and a recognition that the translational highway is bidirectional.
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The development of ␤-blockers for the treatment of heart failure was built on a strong foundation that interlaced basic science discoveries with critical observations from investigator-initiated clinical research. Critical observations from the laboratory included the recognition that left ventricular dysfunction was associated with an increase in adrenergic drive, 7, 8 the observation that the administration of an adrenergic agonist could recapitulate the heart failure phenotype, 9, 10 the finding that there were functional ␤1and ␤2-ARs on the ventricular myocardium, and that there was a shift in the ratio of ␤1to ␤2-ARs in the failing heart. 11 Unique to the development of the scientific rationale underlying the development of ␤-blockers was the ability of the Bristow group to use isolated ventricular muscle and membrane preparations obtained from normal and failing human heart as a model system. These early studies at the bench were the underpinnings of the early investigator-initiated clinical studies.
A sine quo non of translational research is that its success is due at least in part to scientific efforts that are both collaborative and multidisciplinary. This was certainly the case for the development of ␤-blocker therapy. Important clinical observations came not just from the work at Stanford by Bristow and his colleagues, but also from Eugene Braunwald and colleagues at Harvard; Kanu Chaterjee and his group at UCSF; Jay Cohn and colleagues at the University of Minnesota; the seminal work of Ake Hjalmarson, Finn Waagstein, and Karl Swedberg in Goteborg, Sweden; and studies by a large group of investigators in Australia and New Zealand. At the basic science level, large collaborative groups at numerous institutions made seminal observations regarding our understanding of adrenergic signaling in the heart including identification of the role of Ca 2ϩ /calmodulin kinase II (National Institute on Aging, Baltimore, MD), 12 type VI adenylyl cyclase (University of California, San Diego), 13 ␤adrenergic receptor kinases (Duke University and Jefferson Medical College), 14, 15 ␤-arrestin (Duke University), 16 ERK 1/2 (University of Cincinnati), 17 and the cardiotoxic effects of overexpression of the ␤1and ␤2-ARs (the University of Colorado and Duke University). 18, 19 Another important component that led to the successful development of ␤-blockers and one whose importance is less well recognized was the perseverance on the part of the investigators and the fortitude of the companies that sponsored the early trials. When early studies with the ␤-blocker acebutolol failed to demonstrate salutary benefits 20 and the nonselective ␤-blocker propranolol was associated with an unacceptable adverse event profile, 21 investigators pursued newer agents with vasodilator activity, hypothesizing that the presence of vasodilator activity would allow for better tolerance. Just as important, when the nonselective ␤-blocker carvedilol failed to meet its primary end point of an improvement in submaximal exercise in 2 phase III pivotal trials, 22, 23 the sponsors recognized the importance of a trend for reduction in mortality and a reduction in cardiovascular hospitalizations in the PRECISE trial and a statistically significant reduction in both mortality and cardiovascular hospitalizations in the MOCHA trial and pursued the approval and further development of the drug despite the fact that the Federal Drug Administration did not initially grant approval.
Translational research has been described as a "bidirectional" highway that links the bench and the bedside. The relevance of this concept to successful drug development is clearly illustrated in the story of ␤-blockers. Information that was of great importance in understanding the role of ␤-blockers in the treatment of heart failure in humans came from studies that have transitioned from the bedside to the bench such as measures of gene expression in endomyocardial biopsies of patients undergoing ␤-blocker therapy. 24 Most recently, seminal information was obtained when Bristow and Steven Liggett used genomic material obtained from the heart failure patients enrolled in the BEST trial to address the question of why the US patients who had been randomly assigned to received bucindilol did not experience the salutary benefits obtained by the largely ex-US subjects enrolled in other large multicenter heart failure studies including CIBIS II, MERIT-HF, and COPERNICUS. It was this return to the laboratory bench that led to the discovery that bucindolol was not beneficial in patients who harbored a glycine at amino acid 389 of the ␤1-AR gene-a genotype that was overrepresented in the BEST trial. 25 We should not read the story of the development of ␤-blockers for heart failure without reminding ourselves of the importance of mentoring the next generation of translational scientists. Indeed, mentoring is an important component of each of the National Institutes of Health-funded Clinical and Translational Science Centers. Bristow describes the role of his own mentors in each step of his scientific career; however, he fails to point out the fact that he himself mentored many clinician-scientists who, as part of his own group or independently, would make substantive contributions to our understanding of the biology and effectiveness of ␤-blockade.
We would be shortsighted, however, if we believed that the story of the development of ␤-blockers for the treatment of heart failure has reached its end. The ability to design drugs with biased agonist properties may provide the ability to block the maladaptive effects of enhanced ␤-adrenergic signaling while at the same time, selectively engaging a subset of the receptors' intracellular partners that afford cardiac protection may vastly expand the capabilities of ␤-AR antagonists. For example, biased ligands that serve as ␤-AR antagonists but activate ␤-arrestin may provide unique pharmacological and therapeutic efforts. 26 The story of the development of ␤-blockers for the treatment of heart failure also points out the glaring need for comparative effectiveness research. Comparative effectiveness research could identify whether existing generic agents (carvedilol) are equivalent in efficacy to new and more expensive agents (nebivilol) and whether genotype influences the effectiveness of ␤-blockers other than bucindolol. Each time a new agent has entered the marketplace the cost of the drug for patients has increased yet there is no substantive data supporting the comparative efficacy of these new drugs.
At a time when only a paucity of new drugs are able to traverse the obstruction-strewn pathway between the basic science laboratory and clinical implementation, the account of the development of ␤-blockers for heart failure must be viewed as more than simply a historical document. Rather, it should provide an important roadmap for pharmaceutical industry executives and federal regulators. While innovations such as microarray and GWAS data, whole-exome or wholegenome sequencing, and network approaches to understanding human disease may lead to the identification of new and novel therapeutic targets, the translation of new findings to the actual treatment of patients with both rare and common diseases will still require a strong underpinning of basic science, broad collaborative efforts, a bidirectional linkage between the bench and the bedside, and fortitude and perseverance by investigators and sponsor -all fundamental aspects of translational science.
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